¹⁸F-FDG PET/CT of off-target lymphoid organs in CD19-targeting chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma.

ABSTRACT:

Objective

The interplay between systemic inflammation, activity of lymphoid organs and lymphoma activity in CD19-targeting chimeric antigen receptor (CAR)-T-cell immunotherapy, and its significance for response and toxicity, is not well defined.

Methods

Using serial ¹⁸F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT), metabolic parameters of lymphoma and lymphoid organs were analyzed in ten patients receiving Tisagenlecleucel (an autologous CD19 CAR-T cell product) for relapsed or refractory diffuse large B-cell lymphoma. The prevalence and severity of toxicity (e.g., neurotoxicity) were noted.

Results

Achieving remission required early metabolic response (P = 0.0476). Early suppression of metabolic activity of lymphoid or

SUBMITTER: Derlin T 

PROVIDER: S-EPMC7796875 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature